caseintelcaseintel

Mass Tort Data Intelligence

Real-time docket tracking, filing velocity, and litigation intelligence across 50 active mass tort dockets.

ACTIVE TORTS 50·TOTAL CASES 306,033+·NEW THIS WEEK ~951·UPCOMING TRIALS 7·Social Media10K+·Depo-Provera3.5K+↑↑·Hair Relaxer15.1K·Talc / J&J67.2K+·AFFF / PFAS15.3K+·Ozempic NAION73+↑↑·PowerPort3K+·Lyft Assault170+↑↑·
ACTIVE TORTS 50·TOTAL CASES 306,033+·NEW THIS WEEK ~951·UPCOMING TRIALS 7·Social Media10K+·Depo-Provera3.5K+↑↑·Hair Relaxer15.1K·Talc / J&J67.2K+·AFFF / PFAS15.3K+·Ozempic NAION73+↑↑·PowerPort3K+·Lyft Assault170+↑↑·
Market AlertAugust 26, 2026

Meta Settles Mid-Trial — $18B Multi-State AG Deal Ends MDL 3047 Track 2 (47 States + DC + Territories)

Meta agreed to pay up to $18B over 10 years to resolve claims from a broad multi-state AG coalition alleging Instagram and Facebook were designed to addict minors and collected children's data in violation of COPPA. The deal — one of the largest AG settlements in U.S. history — was announced August 26, only 8 days into the Oakland federal trial that began August 18 before Judge Yvonne Gonzalez Rogers. $17.1B goes to the 29-state co-lead group that brought the original 2023 lawsuit (California AG Bonta co-lead); the balance covers the broader 47-state + DC + U.S. territories signatory pool (52 AGs total). Only New Mexico (already won ~$950M at trial) and Florida (AG rejected terms as too weak) are excluded. Beyond the cash, Meta agreed to sweeping platform changes: a 2-hour cumulative daily teen time limit across Facebook and Instagram (disable requires parental consent), blocked access midnight-6am, and muted notifications 8am-3pm on school days. Meta did not admit wrongdoing. META's market reaction was muted — +1.07% intraday to $576.14, adding ~$13.5B to market cap despite the $18B liability (net favorable given the trial's $1.4T theoretical statutory exposure was cleared). Jim Cramer called the market read 'ridiculous' and framed the deal as a 'big break' for Meta. Case-management ripple: the deal removes Meta's federal AG trial risk entirely; the ~2,400 remaining MDL 3047 personal-injury cases (individual plaintiffs, not AG plaintiffs) continue on separate tracks. The August 10 Ninth Circuit Section 230 ruling forced this trial to proceed — Meta chose settlement over verdict once the appellate escape was closed.

Defendant Market Impact

META +1.07% intraday to $576.14 (~$13.5B mkt cap add)
Multi-State Deal
$18B

Verdict Breakdown

In re: Social Media Adolescent Addiction/Personal Injury Products Liability Litigation (MDL 3047, N.D. Cal.) — Track 2 AG settlement
Cash + Terms$17.1B to 29-state co-lead group; balance covers 47 states + DC + territories (52 AGs total); 10 annual installments
Platform Changes2-hr teen time limit; blocked midnight-6am; muted 8am-3pm school hours; no admission of wrongdoing

MDL 3047 Post-Settlement Landscape

~2,400 remaining federal individual-injury cases continue on separate tracks (not resolved)
Trial had been running 8 days when settlement announced; ended mid-trial
Advisory jury under FRCP 39(c) never delivered findings
August 10 Ninth Circuit ruling (Section 230 = defense not immunity) forced trial to proceed → settlement followed
Meta's earlier state liability preserved: K.G.M. $6M + ~$950M NM (verdict + abatement)
Snap, TikTok, Google had already settled out of AG action pre-trial
Florida AG posture leaves possible standalone state action open — outlier risk

Key Developments

$18B multi-state AG settlement announced Aug 26, 2026 — 8 days into Oakland trial

$17.1B to 29-state co-lead group; balance covers 47 states + DC + territories (52 AGs signed)

Only New Mexico (won ~$950M at trial) and Florida (rejected terms) excluded

10-year installment structure; no admission of wrongdoing

Sweeping platform changes: teen time limits, sleep-hour blackouts, school-hour notification mute

META +1.07% intraday — market read as clearing overhang, not distress; Cramer called it a 'big break'

~2,400 individual injury cases in MDL 3047 remain on separate tracks

Browse Archive·1 of 8
Intelligence Feed Network14 active sources
CourtListener / PACER50
Google News RSS84
FDA Drug Alerts335
FDA FAERS1,104
PubMed / NCBI67
ClinicalTrials.gov42
JPML MDL Stats28
Class Action Filings19
Market Data56
Federal Register127
CPSC Recalls15
SEC EDGAR38
DOJ / Legal Enforcement22
CDC MMWR31
Total signals:2,018
Polling every 6–12h

Plaintiff Firm Rankings — Sep 6 – Sep 19, 2026

#FirmCityActive DocketsNewLeadership Status
1Motley Rice LLCMt. Pleasant, SCSocial Media, AFFF, Talc45PSC — MDL 3047, MDL 2873
2Levin Papantonio RaffertyPensacola, FLAFFF, Hair Relaxer, PowerPort38Co-Lead — MDL 2873
3Beasley AllenMontgomery, ALParagard, Ozempic, Hair Relaxer32PSC — MDL 3094, MDL 2750
4Seeger Weiss LLPNew York, NYAcetaminophen, FreeStyle Libre, Social Media30Co-Lead — MDL 3043
5Wisner BaumLos Angeles, CAAcetaminophen, Depo-Provera, Social Media28PSC — MDL 3043, MDL 3140
6Slater Slater SchulmanNew York, NYUber, Lyft, Social Media25Lead — MDL 3084
7TorHoerman LawEdwardsville, ILHair Relaxer, Paragard, Social Media22PSC — MDL 3060
8Weitz & LuxenbergNew York, NYFreeStyle Libre, 1,4-Dioxane, Talc20PSC — MDL 2738

MDL Case Count Tracker — Sep 6 – Sep 19, 2026

50 dockets
TortMDL #TotalNew (Wk)TrendKey Development
Tech
Pre-MDL~500+~35
FAST
State AG actions accelerating. Epic Games $520M FTC precedent. MDL formation expected 2026.
Tech
304710,000+~30
ACTIVE
Post-verdict momentum. Meta/Google appeal expected. Federal bellwether Jun 15 on track.
Talc / J&JBorderline
Consumer
273867,200+~45
FILING
CA $950M verdict vacated Mar 17. Continued high-volume filing.
Consumer
3060~15,100~25
ACTIVE
BELLWETHER SELECTION: Judge Rowland selected 3 cases Apr 1.
Chemical
287315,250+~40
FILING
Steady high-volume intake. Motley Rice, Levin Papantonio active.
Device
284623,800+~50
FILING
Continued largest filing volume.
Pharma
31403,490+~40
FAST
Expert deps completed Mar 20. Preemption motion under advisement.
Pharma
3092~8,500~5
FLAT
Bellwether discovery continues.
Pharma
30943,546+~20
ACTIVE
Entering critical Daubert/SJ phase.
Device
30813,044+~40
ACTIVE
TRIAL IMMINENT: Cook bellwether Apr 21.
Paragard IUDBorderline
Device
27503,600+~25
FILING
Beasley Allen, TorHoerman active. Mediation ongoing.
Pharma
316373+~19
FAST
Separate MDL created Dec 2025. NJ MCL active in parallel.
Pharma
3043~3,025~25
FILING
Seeger Weiss, Wisner Baum active.
Tech
3171~170~20
FAST
Rapid intake continues.
Tech
30842,075+~15
FILING
Slater Slater Schulman active.
Device
3172~400~10
FILING
Mediation ongoing. Bellwether May 26.
Pharma
318018+~5
FAST
JPML MDL motion filed. Ruling expected soon.
Consumer
Pre-MDL~325~25
FAST
Pre-MDL. Multiple firms active.
Device
Pre-MDL~215~15
FILING
Seeger Weiss, Weitz & Luxenberg active.
Chemical
E.D.N.Y30+~3
FILING
Weitz & Luxenberg, Napoli Shkolnik active.
Consumer
Pre-MDL~22~4
FILING
JPML Birmingham hearing Mar 26. Ruling imminent.
Chemical
27414,200+~15
ACTIVE
Bayer settlement ongoing. New cases still filing.
Chemical
E.D.N.C.95,000+~200
FILING
PACT Act claims. Federal government defendant.
Pharma
29242,100+~2
FLAT
Most claims dismissed. Science rulings unfavorable.
Chemical
30045,400+~35
FILING
Parkinson's disease link. Syngenta/Chevron defendants.
Consumer
Pre-MDL~500~20
FAST
Emerging ovarian cancer claims separate from J&J.
Consumer
30261,800+~12
ACTIVE
Abbott/Mead Johnson. Premature infant NEC claims.
Pharma
3043~3,025~25
FILING
Autism/ADHD link. Retailers as defendants.
Pharma
Pre-MDL~200~10
FAST
Hearing loss side effect. Horizon Therapeutics.
Device
3014750+~8
ACTIVE
Foam degradation. Cancer risk claims.
ElmironBorderline
Pharma
29731,200+~3
FLAT
Vision damage. Settlement discussions ongoing.
Device
3044900+~10
FILING
Polyethylene insert failures.
BelviqOpen
Pharma
Pre-MDL~150~8
FAST
Cancer risk. Pulled from market 2020.
Chemical
Pre-MDL~400~15
FAST
PFAS exposure. Emerging litigation.
Consumer
Pre-MDL~300~10
FILING
Heavy metals in baby food. Multiple defendants.
FluoroquinoloneBorderline
Pharma
Pre-MDL~250~2
FLAT
Cipro/Levaquin. Peripheral neuropathy.
Pharma
278912,000+~5
FLAT
Nexium/Prilosec. Kidney damage. Mostly settled.
Device
26413,800+~3
FLAT
Bard/Cook. Filter migration/fracture.
RisperdalClosed
Pharma
2767900+~2
FLAT
Gynecomastia. Most cases resolved.
Device
2885Settled0
FLAT
$6B settlement complete. Monitoring ongoing.
ValsartanClosed
Pharma
28751,400+~3
FLAT
NDMA contamination. Cancer claims.
Consumer
30384,500+~15
ACTIVE
Youth vaping. School district claims.
Other
Pre-MDL~50~3
FAST
Antitrust. PGA merger implications.
Tech
Pre-MDL~100~5
FILING
Driver-on-passenger assault claims.
Tech
Pre-MDL~75~4
FAST
Data privacy violations. CCPA claims.
Chemical
23422,500+~10
FILING
Environmental contamination. School claims.
Consumer
2738Part of Talc~20
FILING
Subset of Talc MDL.
Pharma
Pre-MDL~100~5
FAST
Autoimmune injury claims. Merck defendant.
Device
22444,000+~2
FLAT
DePuy/Stryker. Mostly resolved.
Pharma
Pre-MDL~50~3
FAST
Immune-related organ failure. Merck defendant.

Critical Dates — Next 60 Days

11 events
DateDocketEventInvestor Significance
Apr 1Hair Relaxer MDL 3060Bellwether case selection by Judge RowlandSets timeline for first federal trial; key valuation signal
Apr 7Social Media MDL 3047Expert report deadline — algorithmic amplificationCore liability theory; affects Daubert outcomes
Apr 10Social Media (NM State)Google appeal filing deadlineAppellate strategy signals settlement posture
Apr 14Social Media JCCP 5255CA state coordination hearingState-level consolidation affects case volume projections
Apr 14Social Media (NM State)Post-trial motions deadlineJNOV ruling could modify $2.1B verdict
Apr 21Bard PowerPort MDL 3081Cook Medical bellwether trial beginsFirst trial in catheter port docket; high settlement leverage
May 5Depo-Provera MDL 3140Preemption motion ruling expectedThreshold legal issue — dismissal risk if granted
May 12Ozempic MDL 3094Daubert hearing — general causation expertsMake-or-break for GLP-1 litigation viability
May 26Cartiva SCI MDL 3172First bellwether trialInitial trial outcome sets negotiation baseline
Jun 2Talc MDL 2738J&J 3rd prepackaged bankruptcy hearingCould resolve or further delay 67K+ claims
Jun 15Social Media MDL 3047Federal bellwether trial beginsLandmark federal trial; massive settlement implications

New Filings — Sep 6 – Sep 19, 2026

CaseDefendantCourtTheoryLead Firm
Rodriguez v. Meta PlatformsMeta Platforms, Inc.N.D. Cal.Product liability — algorithmic addictionMotley Rice LLC
Thompson v. Bard MedicalBard Medical / BDD. Ariz.Device failure — catheter fractureLevin Papantonio
Williams v. Pfizer Inc.Pfizer Inc.S.D.N.Y.Failure to warn — Depo-Provera meningiomaWisner Baum
Garcia v. Novo NordiskNovo Nordisk A/SE.D. Pa.GLP-1 gastroparesis / bowel obstructionBeasley Allen
Davis v. Lyft, Inc.Lyft, Inc.N.D. Cal.Negligent hiring — sexual assaultSlater Slater Schulman
Chen v. Abbott LabsAbbott LaboratoriesN.D. Ill.Device defect — FreeStyle Libre burnsSeeger Weiss LLP
Investor Intelligence

Analyst Notes & Portfolio Strategy

Priority assessments, stage analysis, and portfolio positioning across active mass tort dockets.

Analyst Notes — Investor Outlook

Social Media Youth Addiction

Elevated Priority

The NM verdict fundamentally shifts the litigation landscape. Federal bellwether on June 15 is the next major catalyst. Expect heightened settlement pressure on Meta/Google. Monitor appellate timeline closely — a sustained verdict dramatically increases portfolio exposure.

View docket details →

Talc / J&J

Bankruptcy Watch

Third prepackaged bankruptcy attempt (June 2 hearing) remains the central variable. CA verdict vacation adds complexity. Resolution of 67K+ claims hinges on bankruptcy court approval of $8.9B trust proposal.

View docket details →

Hair Relaxer

Trial Preparation

Bellwether selections signal active progression. Three cases chosen April 1 will define trial strategy. L'Oreal, Revlon exposure significant. Watch for Daubert rulings on causation experts in coming weeks.

View docket details →

Depo-Provera

Elevated Priority

Preemption ruling (expected May 5) is threshold issue. If denied, rapid case growth likely accelerates. Pfizer exposure could be substantial given long market history and meningioma causation evidence.

View docket details →

Ozempic / GLP-1

Critical Juncture

May 12 Daubert hearing is make-or-break. Favorable ruling opens massive liability exposure for Novo Nordisk and Eli Lilly. Unfavorable ruling could significantly deflate docket. High-stakes binary outcome.

View docket details →

Bard PowerPort

Trial Imminent

Cook Medical bellwether (April 21) is the first catheter port trial. Outcome will set settlement benchmarks. BD/Bard cases to follow. Device failure evidence is strong — favorable plaintiff verdict expected.

View docket details →

Opportunities by Stage

Emerging< 45
·Keytruda Organ Failure
·Dupixent CTCL
·Tepezza
·Belviq
·Gardasil HPV Vaccine
·WeChat Privacy
·LIV Golf Antitrust

Early signals. Pre-MDL formation. First-mover window.

Formation45–55
·Hair Relaxer
·Nitrous Oxide
·Ozempic NAION
·Firefighter Cancer
·ByHeart Formula
·FreeStyle Libre

Active investigation. Firms building inventory.

Active Litigation55–70
·Ozempic / GLP-1
·Bard PowerPort
·Depo-Provera
·Hernia Mesh
·Paraquat
·NEC Baby Formula
·Paragard IUD

Meaningful case volume. Bellwethers approaching.

Maturation70+
·Social Media Addiction
·AFFF / PFAS
·Talc / J&J
·Camp Lejeune
·Roundup / Monsanto
·Juul / E-Cigarettes

Multi-front mass tort. Settlement pressure.

Litigation Stage Tracker
12 Key Dockets
Docket Market

The Diversified Core Portfolio

8 curated mass tort positions across 5 sectors and 4 stages.

8Positions
5Sectors
4Stages
View Portfolio →
Weekly Intelligence Brief

Don't miss a ruling, verdict, or filing.

Every Monday: critical docket developments, filing velocity changes, bellwether outcomes, and portfolio signals — in one email.

2 min read·Free forever·Unsubscribe anytime
Trusted Intel Intake

Upload expert documents into the live docket board

Upload litigation reports, filings, or normalized JSON. Trusted docket facts become homepage overrides when they match a live MDL or tracked docket.

6
Recent Uploads
0
Facts
0
Events
No file selected yet.

Recent Intel Activity

Newest first
May 2026 Litigation Guide
WL · 5/13/2026, 12:56:57 AM
STORED_RAW
Facts 0Events 0
Social Media Harm Intake Criteria Feb 3 2025.pdf
Unknown publisher · 5/13/2026, 12:47:39 AM
STORED_RAW
Facts 0Events 0
Semaglutide NAION Intake Criteria Jul 29 2025.pdf
Unknown publisher · 5/13/2026, 12:47:34 AM
STORED_RAW
Facts 0Events 0
May Update
WL · 5/13/2026, 12:47:29 AM
STORED_RAW
Facts 0Events 0
Diag PDF Upload
Unknown publisher · 5/13/2026, 12:41:33 AM
STORED_RAW
Facts 0Events 0
Diagnostic Test Upload
Claude Diagnostic · 5/13/2026, 12:40:47 AM
TEXT_CAPTURED
Facts 0Events 0